Clinical trial
HGS-ETR2 to Treat Children With Solid Tumors
NCT00428272 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00428272 |
|---|---|
| Title | HGS-ETR2 to Treat Children With Solid Tumors |
| Official title | A Phase I Trial of Monoclonal Antibody HGS-ETR2 (Lexatumumab) With or Without Interferon Gamma in Patients With Refractory Pediatric Solid Tumors |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Ewing's Sarcoma, Osteosarcoma, Neuroblastoma, Rhabdomyosarcoma |
| Intervention type | Drug |
| Interventions | Lexatumumab alone, Lexatumumab in combination, Interferon gamma 1b in combination, Gamma 1b potential expansion |
| Enrollment | 30 |
| Start date | Dec 4, 2006 |
| Primary completion | Apr 28, 2011 |
| Completion | Oct 9, 2015 |
| First posted | Jan 29, 2007 |
| Last update posted | Dec 17, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: